At the 62nd ASMS Conference on Mass Spectrometry and Allied
Topics today, Bruker Corporation (NASDAQ:BRKR) today announced mass
spectrometry-based product introductions for life-science research
and proteomics, for clinical research, for pharma/biopharma/CRO
customers, as well as for applied and industrial markets. The new
systems and solutions are designed to deliver confident analyses
with significantly enhanced performance, productivity and
versatility.
impact(TM) II Mass Spectrometer (Photo:
Business Wire)
Major Bruker Innovations at ASMS 2014:
- New impact II ™ ultra-high resolution
QTOF mass spectrometer with industry-leading further performance
improvements
- A breakthrough, new 21 Tesla magnet for
ultra-high field Fourier Transform Mass Spectrometry (FTMS),
described in a separate joint press release together with
NHMFL
- Opening the next chapter in proteomics,
the unique impact II now enables for the first time ever fast,
intact protein profiling of over 1,000 proteoforms in a single,
less than 30 minute UHPLC-UHR-QTOF run
- New multi-OMICS platform increasing
productivity, versatility, and deeper biological insights,
including full MaxQuant software support and new Compass™
PathwayScreener™ software
- New ToxScreener™ solution for
comprehensive forensic toxicology on unknowns
- European launch of Toxtyper™ 1.1, a
robust and easy to use forensic and clinical research solution for
routine, fast, push-button toxicology on approximately 900
compounds
- ASMS debut of new autoflex™ speed MALDI
TOF(/TOF) system with Bruker 2 kHz smartbeam™-II laser to enhance
productivity in protein analysis, MALDI imaging and MALDI Biotyper
applications
The new research capabilities, analytical utility and
productivity will be presented in Bruker’s ASMS users’ symposium,
breakfast workshops, and hospitality suite with emphasis on the
following market/applications areas: systems biology, proteomics
and metabolomics; biologics & pharmaceuticals; MALDI molecular
imaging for pathology research and drug development; petroleomics,
energy and industrial applications; applied markets including food
safety, forensics and toxicology; as well as MALDI Biotyper-based
clinical microbiology. The following sections describe the new
Bruker products in more detail:
impact™ II Mass Spectrometer
The new impact II system is the latest innovation in Bruker’s
unique UHR-QTOF (ultra-high resolution Qq-time-of-flight) mass
spectrometry product line, now with industry-leading >50,000
Full-Sensitivity Resolution (FSR). It offers further enhanced
analytical performance levels for all applications where trace
analysis from complex, high-background matrices is a challenge –
such as proteomics, biomarker research, identification of
impurities, or residue screening.
Due to its industry-leading sensitivity, broad mass-transfer ion
optics and fast 50 Gbit/sec sampling technology, a dynamic range of
5 orders of magnitude is achieved at UHPLC speeds, with up to 50 Hz
spectrum acquisition. The impact II features industry-leading
isotopic pattern accuracy, a prerequisite for automated, reliable
molecular formula determination of low abundance compounds in nano-
and UHPLC peaks.
The enhanced capabilities and versatility of this novel UHR-QTOF
drive more productivity for all accurate mass , high dynamic range
applications in academia and industry, including:
- Faster and cost-effective analysis of
sub-units of monoclonal antibodies, which can now be fully isotope
resolved.
- Sustainable identification and
quantification performance for in-depth quantitative analysis of
proteomics samples, including bottom-up proteomics, glycomics and
the identification of PTMs
- High-throughput proteoform screening of
intact proteins with isotopic resolution up to 30 kDa. This unique
assay allows the screening of well over 1,000 proteoforms in a
single 20-30 min UHPLC-UHR-QTOF run. This breakthrough in
proteomics is expected to provide an enabling technology for
accelerated biomarker identification and validation, and for faster
progress towards clinical proteomics.
- Deep insight into complex metabolomics
samples in targeted and non-target analysis by integrated workflows
using ProfileAnalysis™ software plus the new Compass
PathwayScreener software to pinpoint biomarkers.
- Better selectivity and specificity for
the new Bruker solution in forensic toxicology, ToxScreener, which
comes with accurate mass libraries developed together with leading
forensic toxicology laboratories.
- Unique Instant Expertise™ software for
intelligent self-optimizing MS/MS acquisition to establish optimal
experimental conditions independent of sample amount or complexity.
This translates into higher productivity and expert-caliber results
- the first time.
These features ensure that the impact II delivers the fastest
time-to-success for customers across a broad applications ranging
from small molecule identification and characterization; to food
safety, forensic and toxicology screening, metabolomics,
pharmaceuticals, and bottom-up proteomics, proteoform screening to
antibody analysis.
Multi-OMICS Knowledge Generation Platform
Bruker is driving the quest for deeper insights and taking
‘omics’ knowledge generation to new heights with the new additions
improving productivity and versatility in areas such as bottom-up
proteomics, glycomics, quantitative proteomics, intact protein
analysis, post-translational modifications and metabolomics.
“We have been using the Impact since almost a year for routine
shot-gun bottom-up proteomics. In combination with the CaptiveSpray
nanoBooster, the instrument has provided an excellent level of
sustainable performance, being capable of delivering untouched
performance for over 6-8 weeks of 24/7 use. This is of tremendous
importance for the success of our label-free measurement
campaigns,” said Professor Alain Van Dorsselaer, LSMBO in
Strassbourg, France.
To strengthen its bioinformatics platform, Bruker has
collaborated with developers in the group of Professor Matthias
Mann to add support for Bruker UHR-QTOF data to the
state-of-the-art quantitative proteomics MaxQuant software designed
for analyzing large mass-spectrometric data sets. It is
specifically aimed at high-resolution MS data. Several labeling
techniques as well as label-free data processing workflows are
supported and in addition MaxQuant enables researchers to utilize
the full potential of mass spectrometry driven proteomics in
multi-OMICS approaches.
In metabolomics there is an increasing need for efficient data
processing tools, and Bruker has strengthened its bioinformatics
offering with Compass™ PathwayScreener software to provide a new
layer of insight into metabolomics samples. With the new Compass
PathwayScreener, users can get twice the results, performing
pathway-driven, targeted metabolomics analysis on the same dataset
used for non-targeted data mining. The PathwayScreener workflow can
be integrated with Bruker’s market-leading multi-OMICS
bioinformatics platform ProfileAnalysis™ for non-targeted
metabolomics and label free proteomics studies.
Professor J�rn Kalinowski, at the Center for Biotechnology in
Bielefeld, Germany, stated: “Using Compass PathwayScreener we were
able to elucidate novel influences of mutants on metabolic networks
in Corynebacterium glutamicum.”
In addition, Bruker is collaborating with the University of
Alberta to facilitate the development of high-resolution tandem MS
libraries for improved workflows in metabolomics. Professor Liang
Li explained: “As a co-PI of the Human Metabolome Database (HMDB)
project, my laboratory generated the original MS/MS spectral
library of about 800 human metabolites using low-resolution triple
quadrupole mass spectrometry. We are delighted to collaborate with
Bruker to produce a new Human Metabolite MS/MS spectral library
with much improved spectral quality. This library, along with an
automated acquisition and processing strategy, allows users to
identify metabolites very quickly with high confidence.”
Dr. Ole Vorm, the Bruker Daltonics Vice President for the
Life-Science Research & Proteomics business unit, commented:
“The new products deliver outstanding and robust performance in a
very accessible and cost-effective platform. We are conscious of
enhancing the reach and capabilities of UHF-QTOF and nano-ESI such
that we make this innovative technology readily available and
accessible - also for biologists who may not be mass-spec experts.
Finally, our proteomics customers are excited about our
breakthrough, rapid proteoform screening technology on the impact
II, as well as its about 50% higher resolution for bottom-up
proteomics, at full sensitivity and under UHPLC fast analysis
conditions.”
ToxScreener, a Forensic Toxicology Solution based on
Accurate Mass, High Dynamic Range LC-MS/MS
The ToxScreener, a new accurate mass, high dynamic range
forensic toxicology solution for Bruker QTOF systems, incorporates
broadband CID (bbCID) acquisition to provide a rapid and reliable
way for scientists to confidently screen for hundreds or even
thousands of known or previously unknown compounds of forensic
relevance, delivering the highest degree of confidence, and data
that is defensible in court.
The ToxScreener enables forensic toxicologists to keep up with
the detection and identification of both the ‘traditional,
established’ drugs of abuse, as well to detect new designer drugs
that are rapidly emerging across the globe. At the heart of the
ToxScreener, is a high quality, accurate mass database covering
drugs of forensic relevance allowing users to attain enhanced
levels of confirmation for conclusive identification compared to
alternative screening techniques. The Bruker ToxScreener bbCID
accurate mass forensic database was developed in close
collaboration with toxicologists at the forensic institutes at the
universities of Freiburg, Germany and Helsinki, Finland.
Professor Ilkka Ojanperä of the Laboratory of Forensic
Toxicology at the University of Helsinki, said: “We have applied
the bbCID concept using Bruker LC-TOF-MS for general forensic drug
screening in urine since 2010. In 2013, we switched to the newest
UHPLC-UHR-QTOF mass spectrometry technology to attain enhanced
sensitivity for drugs-of-abuse and designer drug forensic
screening, covering critical low concentration compounds like THC
acid, buprenorphine, LSD, and synthetic cannabinoids. This approach
has been well received amongst our customers, being an even bigger
success than we expected, such that immunological methods in our
laboratory have now been replaced by the Bruker QTOF bbCID
workflow. The bbCID concept has been carefully validated against
spectral library comparison, and it has proven to deliver equal
confidence, but with a much higher efficiency, significantly
increasing our productivity. Our forensic screening method has now
been accredited by the Finnish Accreditation Service.”
High-throughput, Robust Toxtyper 1.1 Solution Automatically
Analyzes for 900 Known Toxicology Target Compounds in 12
Minutes
The new Toxtyper 1.1 routine analytical solution includes novel
library identification algorithms and reporting with a high-quality
library update to over 900 target compounds. In addition, the
Toxtyper 1.1 workflow now also comes with a targeted drugs-of-abuse
sub-library. Key technologies to achieve robust and reliable
toxicology identification performance include continuous,
zero-delay positive/negative ion switching, high MS/MS specificity
and novel, on-the-fly MS3 confirmation. The new Toxtyper 1.1 search
algorithms now also are fully compatible with the recently
published “Maurer/Wissenbach/Weber LC-MSn library of Drugs, Poisons
and their Metabolites”, an ion trap library which holds over 1,000
parent compounds and 2,700 metabolites.
Novel software tools for automated assignment of structures to
fragment ions offer additional metabolites identification and
structure verification by MSn. Toxtyper 1.1 now supports sample
preparation SOPs for high sensitivity detection of drugs in urine
and serum. Toxtyper is a Research Use Only solution presently
available only in Europe in selected countries. For more
information on the amaZon speed mass spectrometer, please visit
www.bruker.com
ASMS Debut of autoflex™ speed MALDI-TOF(/TOF) with 2 kHz
Smartbeam™ Laser
The updated autoflex speed mass spectrometer incorporates
of numerous advancements to further enhance data quality,
acquisition speed, class-leading mass and dynamic range, all with
robust and efficient performance. It further extends the
applications of MALDI TOF/TOF in protein sequencing, biomarker
discovery, polymer analysis, lipid and glycan analysis, molecular
imaging, as well as in high-throughput MALDI Biotyper
microbiological identification. The autoflex speed
incorporates the patented smartbeam™-II laser, now with up to 2 kHz
repetition rate and true-pixel image resolution at 20 µm, along
with other features that enhance its capabilities including:
- Unique FAST-SRM mode for single
reaction monitoring in imaging drugs and metabolites in
tissue.
- Expanded high-resolution mass range for
polymers and top-down, intact protein sequencing for long sequence
readouts.
- FlashDetector™ technology to
increase resolution and prevent signal saturation for complex
samples
- Self-cleaning Ion Source cleans the
source in minutes to improve up-time with minimal operator
maintenance.
- Optimized software packages for
numerous applications e.g. protein, peptide or polymer analysis, as
well as MALDI imaging, clinical research and the MALDI Biotyper
IVD-CE workflow.
About Bruker Corporation
Bruker Corporation is a leading provider of high-performance
scientific instruments and solutions for molecular and materials
research, as well as for industrial and applied analysis. For more
information about Bruker Corporation (NASDAQ:BRKR), please visit
www.bruker.com.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20140616005495/en/
Bruker CorporationMedia Contact:Tony Lewtas, 978-663-3660
ext.1212tony.lewtas@bruker.comorInvestor Contact:Joshua
Young, 978-663-3660 ext.1479Vice President of Investor
Relationsjoshua.young@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024